参苓白术散加减治疗肝郁脾虚型慢性乙型肝炎临床观察

Clinical Observation on Modified Shenling Baizhu Powder in the Treatment of Chronic Hepatitis B with Liver Stagnation and Spleen Deficiency

目的探讨参苓白术散加减治疗肝郁脾虚型慢性乙型肝炎的临床效果。方法随机选取2015年3月—2017年5月本院收治的60例慢性乙型肝炎患者,按照随机分配原则分为观察组和对照组,各30例。对照组患者给予恩替卡韦分散片口服,联合复方甘草酸苷片进行护肝治疗,观察组在对照组的治疗基础上运用参苓白术散加减治疗。对比2组的治疗效果以及安全性。结果治疗前2组患者ALT、AST、TBIL水平比较无明显差异(P> 0. 05);治疗后2组ALT、AST、TBIL水平均下降,观察组明显低于对照组(P <0. 05);治疗后2组患者中医证候评分明显下降,观察组明显低于对照组(P <0. 05),观察组临床总有效率96. 67%明显高于对照组73. 33%(P <0. 05)。结论参苓白术散加减治疗肝郁脾虚型慢性乙肝的临床效果更加明显,且安全性可靠。

Objective To investigate the clinical effect of modified Shenling Baizhu powder in the treatment of chronic hepatitis B with liver stagnation and spleen deficiency.Methods 60 patients with chronic hepatitis B admitted in our hospital from March 2015 to May 2017 were randomly selected and observed according to the principle of random distribution.The patients in the control group were given entecavir dispersible tablets orally and compound glycyrrhizin tablets for liver protection,and the observation group was treated with Shenling Baizhu powder on the basis of the treatment in the control group.The efficacy and safety of the two groups were compared.Results There was no significant change in ALT,AST,TBIL level between the two groups before treatment(P>0.05).After treatment,the level of ALT,AST,TBIL in the observation group was significantly lower than that in the control group(P<0.05).After treatment,the scores of TCM symptoms in the observation group were significantly lower than those in the control group(P<0.05).The clinical effective rate of the observation group and the control group was 96.67%and 73.33%respectively(P<0.05).Conclusion The clinical effect of Shenling Baizhu powder in treating chronic hepatitis B with liver stagnation and spleen deficiency is more obvious,and it is safe and reliable.